Integrative analysis of lactylation patterns reveals prognostic biomarkers and therapeutic targets in pancreatic cancer
Cancer Letters · 2026-07 · 651 · 218536
DOI: 10.1016/j.canlet.2026.218536 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-07. Verfasst von Wenbo Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical Unive…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Biomarkers, Tumor, Lactic Acid, Adenocarcinoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pancreatic adenocarcinoma (PAAD) is a highly lethal malignancy with limited prognostic biomarkers and therapeutic targets. Lactate-driven lactylation has recently emerged as an important regulator of cancer progression, but its role in PAAD remains unclear. In this study, integrative analysis of TCGA and GEO datasets, combined with experimental validation, identified a five-gene lactylation-associated signature (LRP3, TTLL6, TSGA13, PRKCG, and SDK2) that effectively stratified PAAD patients by survival risk. High-risk tumors displayed an immunosuppressive phenotype with reduced immune infiltration, Th2-skewed remodeling, checkpoint activation, and distinct mutational and drug-sensitivity features. Among the signature genes, PRKCG was significantly downregulated in PAAD and associated with advanced disease and worse prognosis. PRKCG overexpression inhibited tumor cell proliferation, migration, invasion, and xenograft growth, while enhancing apoptosis. Mechanistically, lactate-induced lactylation impaired PRKCG-dependent activation of the p53 pathway without altering PRKCG expression, and mutation of predicted lactylation sites partially rescued this effect. These findings define a lactylation-associated prognostic model for PAAD and highlight the lactate-PRKCG-p53 axis as a potential therapeutic vulnerability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China; Changhai Clinical Research Center, Changhai Ho…
- Department of Gastroenterology, Changhai Hospital, National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.
- Changhai Clinical Research Center, Changhai Hospital, Shanghai, China.
- Changhai Clinical Research Center, Changhai Hospital, Shanghai, China. Electronic address: zhaoshenli5610@hotmail.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhu, W., Ma, C., Zhao, X., Song, Y., Li, J., Feng, Y., Sun, F., Li, Z., Du, Y., Kong, X., & Kong, F. (2026). Integrative analysis of lactylation patterns reveals prognostic biomarkers and therapeutic targets in pancreatic cancer. Cancer Letters, 651, 218536. https://doi.org/10.1016/j.canlet.2026.218536
Vancouver
Zhu W, Ma C, Zhao X, Song Y, Li J, Feng Y, et al. Integrative analysis of lactylation patterns reveals prognostic biomarkers and therapeutic targets in pancreatic cancer. Cancer Letters. 2026;651:218536. doi:10.1016/j.canlet.2026.218536
BibTeX
@article{Zhu2026,
author = {Zhu, Wenbo and Ma, Congjia and Zhao, Xintong and Song, Yingxiao and Li, Jiayi and Feng, Yongpu and Sun, Fengyuan and Li, Zhaoshen and Du, Yiqi and Kong, Xiangyu and Kong, Fanyang},
title = {Integrative analysis of lactylation patterns reveals prognostic biomarkers and therapeutic targets in pancreatic cancer},
journal = {Cancer Letters},
year = {2026},
volume = {651},
pages = {218536},
doi = {10.1016/j.canlet.2026.218536}
}
EUVIMED